What's Happening?
The FDA has placed a full clinical hold on Aardvark Therapeutics' Prader-Willi syndrome drug, ARD-101, due to cardiac concerns observed in trials. The hold affects ongoing Phase 3 trials and an open-label extension study. The decision follows earlier
pauses in trials after cardiac issues were detected in healthy volunteers. Aardvark is working with the FDA to address these concerns and determine the future of the drug.
Why It's Important?
The FDA's decision highlights the critical role of safety in drug development and the potential impact of adverse findings on clinical trials. It underscores the importance of thorough safety evaluations and the challenges biotech companies face in navigating regulatory requirements. The hold also raises questions about the future of treatments for rare diseases like Prader-Willi syndrome and the implications for patients awaiting new therapies.
